FONT-SIZE Plus   Neg

EXACT Sciences Says It Submitted Final Module Of PMA For Cologuard To The FDA

EXACT Sciences Corp. (EXAS), a molecular diagnostics company focused on the early detection and prevention of colorectal cancer, Monday said that it submitted the final module of the premarket approval or PMA for Cologuard, the company's stool DNA or sDNA colorectal cancer screening test, to the U.S. Food and Drug Administration or FDA. The final module which was submitted on June 7, comprised of data from the company's DeeP-C clinical trial. The trial analyzed data from about 10,000 patients at 90 sites between the ages of 50 and 84 who were at average risk for colorectal cancer.

EXACT Sciences also announced that the role of COO Maneesh Arora would now also include the oversight of U.S. sales and marketing. The company is also in the search for a senior financial officer.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Shares of Daimler AG were losing around 3 percent in the morning trading, after the German auto giant trimmed its forecast for fiscal 2016 revenues and unit sales, while it backed adjusted EBIT view. Meanwhile, in the third quarter, the company recorded higher earnings and revenues, with increased sales volumes. German software developer SAP SE reported Friday lower profit in its third quarter due to higher stock-based compensation expense. However, revenues were higher. All regions posted improved results. Citing the strong cloud performance, the company said it is confident to deliver a strong fourth quarter, and also raised its full-year 2016 operating profit and revenue outlook. Shares of Ericsson were declining around 3 percent in the early morning trading after the Swedish telecom operator reported Friday a loss in its third quarter as net sales were hurt by weaker demand for mobile broadband, especially in markets with weak macro-economic environment.
comments powered by Disqus
Follow RTT